Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

  • Immuron Limited IMRN has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials.
  • The studies were conducted independently by the Hadassah Medical Center, Israel.
  • IMM124E is used to manufacture Immuron's flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn. 
  • The paper examines the ability of IMM-124E to promote antiviral interferon-γ (IFNγ) T cell responses in a mouse model and five healthy human volunteers. 
  • The research study aimed to determine the ability of IMM-124E to promote antiviral interferon γ (IFNγ) T cell responses. 
  • In the preclinical study, data showed that IMM124E enhanced antiviral immunity across the viral strains tested. A similar response was observed in the human study. 
  • Healthy volunteers received IMM-124E orally, at a daily dose of 600 mg for four consecutive days and 1200 mg for an additional day. 
  • The preliminary clinical data suggested a similar effect in humans in augmenting antiviral responses against COVID-19 and Hepatitis B. 
  • Immuron previously reported research investigations on IMM-124E demonstrated neutralizing activity against COVID-19 infection.
  • Price Action: IMRN stock is up 11.90% at $3.94 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!